Search research articles
Contact Us
Filters
Showing results (1-10 of 15) with videos related to
Page
of 2
Sort By:
Molecular and Cellular Biology
|
October 16, 2004
Identification of the proteins required for biosynthesis of diphthamide, the target of bacterial ADP-ribosylating toxins on translation elongation factor 2
Shihui Liu, G Todd Milne, Jeffrey G Kuremsky, et al.
Handbook of Experimental Pharmacology
|
July 6, 2019
Correction to: Soluble Guanylate Cyclase Stimulators and Activators
Peter Sandner, Daniel P Zimmer, G Todd Milne, et al.
Handbook of Experimental Pharmacology
|
January 29, 2019
Soluble Guanylate Cyclase Stimulators and Activators
Peter Sandner, Daniel P Zimmer, G Todd Milne, et al.
Plos One
|
May 3, 2014
Fatty acid amide hydrolase (FAAH) inhibitors exert pharmacological effects, but lack antinociceptive efficacy in rats with neuropathic spinal cord injury pain
Aldric T Hama, Peter Germano, Matthew S Varghese, et al.
Cellular and Molecular Life Sciences : CMLS
|
October 14, 2024
Pharmacologically increasing cGMP improves proteostasis and reduces neuropathy in mouse models of CMT1
Seth M Moore, Joseph Gawron, Mckayla Stevens, et al.
JACC. Basic to Translational Science
|
September 18, 2023
Stimulation of Erythrocyte Soluble Guanylyl Cyclase Induces cGMP Export and Cardioprotection in Type 2 Diabetes
Tong Jiao, Aida Collado, Ali Mahdi, et al.
Antimicrobial Agents and Chemotherapy
|
September 29, 2006
Inhibition of filamentation can be used to treat disseminated candidiasis
Stephen P Saville, Anna L Lazzell, Alexander P Bryant, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
October 23, 2010
Fatty acid amide hydrolase (FAAH) inhibition reduces L-3,4-dihydroxyphenylalanine-induced hyperactivity in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned non-human primate model of Parkinson's disease
Tom H Johnston, Philippe Huot, Susan H Fox, et al.
Clinical Pharmacology in Drug Development
|
November 14, 2018
A Randomized, Placebo-Controlled, Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Soluble Guanylate Cyclase Stimulator Praliciguat in Healthy Subjects
John P Hanrahan, James D Wakefield, Phebe J Wilson, et al.
Pharmacology Research & Perspectives
|
April 22, 2020
Pharmacokinetics, mass balance, tissue distribution, metabolism, and excretion of praliciguat, a clinical-stage soluble guanylate cyclase stimulator in rats
Ali R Banijamali, Andrew E Carvalho, James D Wakefield, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 15) with videos related to
Sort By:
Page
of 2
Molecular and Cellular Biology
|
October 16, 2004
Identification of the proteins required for biosynthesis of diphthamide, the target of bacterial ADP-ribosylating toxins on translation elongation factor 2
Shihui Liu, G Todd Milne, Jeffrey G Kuremsky, et al.
Handbook of Experimental Pharmacology
|
July 6, 2019
Correction to: Soluble Guanylate Cyclase Stimulators and Activators
Peter Sandner, Daniel P Zimmer, G Todd Milne, et al.
Handbook of Experimental Pharmacology
|
January 29, 2019
Soluble Guanylate Cyclase Stimulators and Activators
Peter Sandner, Daniel P Zimmer, G Todd Milne, et al.
Plos One
|
May 3, 2014
Fatty acid amide hydrolase (FAAH) inhibitors exert pharmacological effects, but lack antinociceptive efficacy in rats with neuropathic spinal cord injury pain
Aldric T Hama, Peter Germano, Matthew S Varghese, et al.
Cellular and Molecular Life Sciences : CMLS
|
October 14, 2024
Pharmacologically increasing cGMP improves proteostasis and reduces neuropathy in mouse models of CMT1
Seth M Moore, Joseph Gawron, Mckayla Stevens, et al.
JACC. Basic to Translational Science
|
September 18, 2023
Stimulation of Erythrocyte Soluble Guanylyl Cyclase Induces cGMP Export and Cardioprotection in Type 2 Diabetes
Tong Jiao, Aida Collado, Ali Mahdi, et al.
Antimicrobial Agents and Chemotherapy
|
September 29, 2006
Inhibition of filamentation can be used to treat disseminated candidiasis
Stephen P Saville, Anna L Lazzell, Alexander P Bryant, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
October 23, 2010
Fatty acid amide hydrolase (FAAH) inhibition reduces L-3,4-dihydroxyphenylalanine-induced hyperactivity in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned non-human primate model of Parkinson's disease
Tom H Johnston, Philippe Huot, Susan H Fox, et al.
Clinical Pharmacology in Drug Development
|
November 14, 2018
A Randomized, Placebo-Controlled, Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Soluble Guanylate Cyclase Stimulator Praliciguat in Healthy Subjects
John P Hanrahan, James D Wakefield, Phebe J Wilson, et al.
Pharmacology Research & Perspectives
|
April 22, 2020
Pharmacokinetics, mass balance, tissue distribution, metabolism, and excretion of praliciguat, a clinical-stage soluble guanylate cyclase stimulator in rats
Ali R Banijamali, Andrew E Carvalho, James D Wakefield, et al.
Page
of 2